Patient-specific tumor neoantigen-major histocompatibility complex (Neoantigen-MHC) (Neoantigen-MHC)

Patient-specific tumor neoantigens presented on peptide-MHC complexes are highly specific targets for personalized cancer immunotherapy. These targets consist of mutant peptides, derived from non-synonymous somatic mutations unique to an individual's tumor, which are processed and displayed on the cell surface by Major Histocompatibility Complex (MHC) molecules [1][2]. Because these neoantigens are not present in the normal proteome, they are not subject to central thymic tolerance, allowing for the generation of high-affinity T-cell responses with minimal risk of autoimmunity [3]. The recognition of these complexes by the T-cell receptor (TCR) is a critical step in the adaptive immune system's ability to identify and destroy malignant cells [2][4]. Therapeutic strategies leveraging these targets include personalized mRNA or DNA vaccines, which prime the patient's own immune system, and adoptive cell therapies using T-cells engineered with neoantigen-specific TCRs [3]. The identification and selection of these targets require advanced genomic sequencing and bioinformatic algorithms to predict which mutations will result in peptides that bind effectively to the patient's specific HLA alleles [4]. Clinical success in targeting these complexes often depends on the tumor's mutational burden and the efficiency of the antigen presentation machinery.

Other names

Neoantigen-HLA complexTumor-specific antigen (TSA)Neoepitope-MHC complexMutant peptide-MHCpHLA complex

Therapeutic agents target these complexes by either vaccinating patients with synthetic neoantigen sequences to stimulate endogenous T-cell expansion or by utilizing engineered T-cell receptors (TCRs) and bispecific molecules that directly recognize the mutant peptide-MHC complex on the tumor cell surface [3][4].